Asthika Goonewardene
Stock Analyst at Truist Securities
(1.12)
# 3,392
Out of 4,810 analysts
92
Total ratings
30.49%
Success rate
-18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.40 | +614.29% | 4 | Apr 1, 2025 | |
| GMAB Genmab | Maintains: Buy | $50 → $45 | $19.51 | +130.65% | 14 | Mar 11, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $3.23 | +364.40% | 6 | Mar 3, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $7 | $4.55 | +53.85% | 3 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Buy | $42 → $43 | $36.54 | +17.68% | 8 | Jan 27, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $12 → $2 | $1.27 | +57.48% | 8 | Jan 10, 2025 | |
| BNTX BioNTech SE | Initiates: Buy | $172 | $99.00 | +73.74% | 1 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $24.62 | +42.16% | 1 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $61.43 | +121.39% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $105.68 | -8.21% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.58 | +2,488.44% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 → $14 | $1.46 | +858.90% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $8.01 | +449.31% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $33.74 | +160.82% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $43.22 | +103.61% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.38 | +189.86% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $0.78 | +2,338.71% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.35 | +2,482.50% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.79 | +4,944.14% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.59 | +4,463.89% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $16.48 | +628.16% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.74 | +3,348.28% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.33 | +4,408.57% | 4 | Aug 23, 2022 |
Autolus Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.40
Upside: +614.29%
Genmab
Mar 11, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $19.51
Upside: +130.65%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.23
Upside: +364.40%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $4.55
Upside: +53.85%
Exelixis
Jan 27, 2025
Maintains: Buy
Price Target: $42 → $43
Current: $36.54
Upside: +17.68%
IGM Biosciences
Jan 10, 2025
Maintains: Hold
Price Target: $12 → $2
Current: $1.27
Upside: +57.48%
BioNTech SE
Jan 10, 2025
Initiates: Buy
Price Target: $172
Current: $99.00
Upside: +73.74%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $24.62
Upside: +42.16%
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $61.43
Upside: +121.39%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $105.68
Upside: -8.21%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.58
Upside: +2,488.44%
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $1.46
Upside: +858.90%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $8.01
Upside: +449.31%
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $33.74
Upside: +160.82%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $43.22
Upside: +103.61%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.38
Upside: +189.86%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $0.78
Upside: +2,338.71%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $0.35
Upside: +2,482.50%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $0.79
Upside: +4,944.14%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.59
Upside: +4,463.89%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $16.48
Upside: +628.16%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.74
Upside: +3,348.28%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.33
Upside: +4,408.57%